-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pancreatic cancer (PaCa) is the fourth-largest cause of cancer-related deaths, with about 55,440 new confirmed cases and 44,330 deaths in the United States in 2018.
because of the asymptomatic nature of the disease and the lack of specific biomarkers for testing, most cases are diagnosed at a late stage, at which point the patient is no longer able to have a cure."
, paCa patients had very poor prognostics, with a five-year relative survival rate of only 8%.
Antibody-drug conjugate (ADC), which typically refers to the association of small molecules with cytotoxicity to complete IgG molecules, is one of the fastest growing class of biotherapy drugs and is currently considered to have the potential to improve PaCa treatment strategies.
because antibodies can selectively target cells that express antigens, this targeted effect can greatly improve the therapeutic effect of the coupled molecules, especially some small molecules that are too toxic to be treated with a single drug.
synthesis of antibody-drug coupleds the study produced a highly refined ADC of anti-EGFR (the skin growth factor complex) by reconnectoring cetuximab (CTX) interchains of disulides with aristatin.
researchers evaluated the activity of the ADC in the CTX-resistant KRAS Mutant Pancreatic Cancer (PaCa) model and predicted the effects of various ADC dosing options on tumors.
antibody-drug coupled with the results of the treatment showed that when Aristatin and CTX??? The average drug for ADC obtained by the selective association of bits: at an antibody ratio (DAR) of 3.9, concentrations and EGFR-dependent cytotoxicity are caused at namore-level concentrations.
in transplant tumor models, ADC was able to inhibit tumor growth and prolong survival without significant signs of toxicity.
mathematical modeling analysis can be obtained to affect the efficacy of ADC key factors, including the density of antigens on tumor cells on the drug targeted regulation.
all in all, the study offers new possibilities for the treatment of pancreatic cancer by re-arranging the antibody-drug duplexium.
.
